Cite
MLA Citation
F. Miglietta et al.. “A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study.” European journal of cancer, vol. 175, n.d., pp. S3–. http://access.bl.uk/ark:/81055/vdc_100169755046.0x00002d